Inquiry

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Samuraciclib hydrochloride hydrate

Cat. No.: IBDI-434768

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects.

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target CDK | Apoptosis
Molecular Weight 552.33
Appearance Solid
Synonyms CT7001 hydrochloride hydrate, ICEC0942 hydrochloride hydrate
SMILES O[[email protected]]1CNCC[[email protected]@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2.Cl.O.[2.5].[3.7]
Purity 98.60%

Storage & Handling

Shipping Room temperature in continental US. May vary elsewhere.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.
! For research use only, not intended for any clinical use.